volume 2, issue 8, PS519 2007
DOI: 10.1097/01.jto.0000283536.72976.25
View full text
|
|
Share

Abstract: Introduction:The five-year survival rate of patients with Non-Small Cell Lung Cancer (NSCLC) after surgical resection ranges from 28% (Stage IIB) to 62% (Stage IA). Although gene expression signatures can be used to predict overall survival in NSCLC patients, there is still a need for novel biomarkers that can identify patients who have the highest likelihood of recurrence and thus might benefit most from adjuvant treatment. Since it has recently been shown that chemotherapy in combination with anti-angiogenes…

Expand abstract

Search citation statements

Order By: Relevance

Citation Types

0
0
0

Paper Sections

0
0
0
0
0

Publication Types

0
0
0
0

Relationship

0
0

Authors

Journals